Non-Sentinel Lymph Nodes Status in Patients With Breast Cancer Operated at Omdurman Teaching Hospital

Table of contents

1.

Results: Total number of 39 female patients under went modified radical mastectomy and level 1 and II axillaries clearances, In 22 patients 56.4% the retrieved sentinel axillary lymph node proved histopathologically to contain malignant cells. In eight patients 20.5% the sentinel lymph node were negative for malignancy and in 09 (23.1%) the SLN was either not found or reactive, Non-sentinel lymph node (NSLN) was found to be positive for malignancy in 11 (28.2%) of the cases.

In 23 (59.0%) it was negative and in 05 (12.8%) it was not found. Out of 22 patients with positive SLN, half of them 11 patients were concomitantly had a positive NSLNs and the other half had a negative NSLN. In the eight patients with negative SLN for malignancy, all of them 08 (100%) had their NSLNs as well were negative for malignancy. These relations were found statistically to be highly significant (P value 0.000) none of the patients in study diagnosis as positive NSLN in negative SLN base.

2. Introduction and Background

entinel lymph node biopsy has been emerged as a safe and accurate procedure for axillary staging in breast cancer and directs the need for further axillary and systemic treatment in patients with early breast cancer (1). The hypothesis that one or a few Authors ? ? : Department of Surgery, Omdurman Teaching Hospital. Author ? : Department of Surgery, College of Medicine & Health Sciences, Bahri University. e-mail: [email protected] lymph nodes receive the first drainage from a tumor site and that a regional node dissection and its morbidity might be avoided if the SLNs prove negative, is logical and intuitive. First suggested by Cabanas in the context of penile cancer and conceived in its modern form in 1992 report by Morton et al. SLN biopsy is rapidly emerging as a new standard of care in melanoma and breast cancer (2). This technique has been studied as a means to improving the quality of life in patients with primary breast cancer it has been proved to be a valuable and accurate tool for the staging of early breast cancers (3). Also has largely replaced level I and level II axillary lymph node dissection (ALND), and identification should be possible in more than 95% of patients (4). The SLN is defined .as the first node or group of node receiving lymph from a tumor area, is usually an axillary node, and is most often in the central group of level I. However it may be an internal mammary node, a supraclavicles node, or even a contralateral axillary node. The status of the SLN has been shown to reflect the presence of metastases in the axillary lymph nodes [non sentinel lymph nodes] (5, 6). a) Techniques used in sentinel lymph node Currently there are two techniques Used for SLNB: radio colloid Tc 99m sulfur colloid and methylene blue dye (isosulfan blue). Most institutions recommend both, some experienced surgeons use one or the other. Methylene blue is as good for SLN mapping agent as Isosulfan blue and is much cheaper. Addition of radiocolloid mapping to blue dye does not achieve a sufficiently higher identification rate to justify the cost. Methylene blue is therefore the agent of choice for SLN mapping in developing countries (7).

3. b) Objectives

To assess the status of axillary lymph nodes in breast cancer to determine further management of the axilla and to assess status of non-sentinel lymph nodes cases of negative SLN patients.

4. II.

5. Patients and Methods

It is prospective interventional study, done in Omdurman Teaching Hospital, department of General Surgery from 27/6/2012 to 30/8/2013 in patients who underwent modified radical mastectomy plus level I and II axillary clearance by injecting methylene blue dye and identifying sentinel lymph node.

6. III. Results

7. a) Patients' demographics

Most of our patients were housewives 23 (59.0%), the rest were laborers, employee or teachers representing, 20.5%, 12.8% and 7.7% respectively. Thirty seven patients (94.9%) were married. Patients seen were coming from different state of the country but 17 (43.6%) from Khartoum state, followed by Kordofan 6 (15.4%), River Nile 5 (12.8%) and Darfour state 4 (10.3%) of the patients.

8. b) Clinical presentation

Breast lump was the common presenting symptom, being the chief complaint in 38 (97.4%) of the patients. followed by breast pain 24 (61.5%) then bloody nipple discharge 09 (23.1%) and no single patient presented with symptoms suggestive of metastases.

9. c) Investigations d) Tumor characteristic

These tumor characteristics were based on clinical assessment. T2 (tumor size 2-5 cm) was the most prevalent accounting for 17 (43.6%) and T4 for only two cases (5.1%). No axillary lymph node was detected on clinical examination on 22 (56.4%) of the patients whereas N1 (single mobile ipsilateral axillary lymph node) was detected in 12 (30.8%). No evidence of distal metastasis was seen in 38 (97.4%) of the cases (Table2). f) Surgical management:

All our patients underwent modified radical mastectomy i.e. mastectomy and axillary clearance. None had breast conserving surgery neither axillary sampling. g) Sentinel lymph node status:

In 22 patients 56.4% the retrieved sentinel axillary lymph node proved histopathologically to contain malignant cells. In eight patients 20.5% the sentinel lymph node were negative for malignancy and in 09 (23.1%) the SLN was either not found or reactive. h) Non-sentinel lymph node status:

Non-sentinel lymph node (NSLN) was found to be positive for malignancy in 11 (28.2%) of the cases. In 23 (59.0%) it was negative and in 05 (12.8%) it was not found.

i) Relation of sentinel and non-sentinel lymph node:

Out of 22 patients with positive SLN, half of them 11 patients were concomitantly had a positive NSLNs and the other half had a negative NSLN. In the eight patients with negative SLN for malignancy, all of them 08 (100%) had their NSLNs as well were negative for malignancy. These relations were found statistically to be highly significant (P value 0.000) as shown in (Table 4) and (Table5). j) Outcome:

The outcome was uneventful in 30 (76.9%), complications were seen in 09 (23.1%) and no mortality was reported in this study. Most of the morbidity were surgical site infection in five (12.8%), seroma 03 (7.7%) or hematoma 02 (5.1%) of the patients respectively. k) Hospital stay:

The mean length of hospital stay was 5.7 (SD± 1.6) days, (ranged 4-10 days). Two third of our patients (66.7%) were discharged home on day five postoperative. The majority of our patients were house wife's about 59% and this may be due to large number of a woman in my country that do not go to work in outside, This is similar to other study (The majority of the patients (76.0%) were house women, while teachers, employee, Farmers, Police women, Sellers, students and mid wives constituted 4.7%, 7.3%, 6.7%, 2.7%, 1.3%, 0.7% and 0.7% respectively) (9).

Low incidence is found in nulliparous patients about 5% of the cases and this does not go with literature which showed high incidence of breast cancer in nulliparous woman (breast cancer is commoner in nulliparous women) (10). This may be due to a little number of woman is nulliparous in Sudan at this age.

Most of our patients have tissues diagnosis by histopathology obtained using true cut needle biopsy. Invasive ductal carcinoma is most common (79. 5%) type of breast malignancy seen in our patients. This is in agreement with the reported 82% -85% in other studies (8, 9,11).

In 5/39 (12.8%) the sentinel lymph node was not found after injecting the dye. This is higher than a rate of 3%-10% reported by other workers (12).

In 22 patients 56.4% the retrieved sentinel axillary lymph node proved histopathologically to contain malignant cells. This is similar to other findings of 50 to 65% (13)however our detection rate is higher than 30 to 40% (14) These differences may be due to different stages of breast cancer at presentation or use of combine Methylene blue dye and radio isotope.

Non-sentinel lymph node was found to be positive for malignancy in 11 (28.2%) of the cases. This rate is lower than (35%) in SLN positive patients (4).

In 23 (59.0%) of our patient negative NSLN was found which is comparable to 50%-70% in other studies. This will enhance the use of sentinel lymph node practice in breast surgery instead of axillaries clearance (3) to avoid a lot of complications found after axillaries surgery ALND is associated with substantial morbidity affecting up to 39% of patients, with a nearly three-fold increased risk of lymph edema or regional sensory loss (9). The rate of false negative results varies from 9.8 % -10.8% (4) to 5% in other study, yet in in other report, it was 1% -2% (14). Some study reported positive NSLN with negative SLN base. If no SLN metastases are identified, the likelihood of additional NSLN involvement is 9.8%, this is comparable to that reported in NSABP-32 and recently by both Lyman and Veronese ranging 9.7%, 8.4%, and 8.8% respectively (4).

V.

10. Conclusion

Figure 1.
Journals Inc. (US)
Figure 2. Table 1 :
1
patient (02.6%) of stage IV. Of stage II (A 12 (30.8%, B
07 (18%)) and stage III (A 08 (20.5%), B 02 (05.1%)
This study included 39 female patients. The (Table3).
mean age was 51.3 (SD± 11.4) years, (range 34-75
years). Eight patients (20.5%) were young below forty
and similar number of cases was elder above 60 years
of age. The majority 23 (59.0%) were in the age group
41-60 years (Table 1).
013
2
Year
2
Volume XIII Issue IV Version I ( ) I Images of the breast was done as U/S in 04 (10.3%) and were below 35 years of age, or breast mammography 08 (20.5%), was suspicious in all. Cyto-pathological diagnosis was conducted to the majority, true cut needle biopsy to 31 (79.5%), fine needle aspiration cytology 19 (48.7%), or excisional biopsy which was the least done in 02 (05.1%) of the patients.
Medical Research
Global Journal of Most of our patients 19 (48.8%) were stage II, 10 (25.6%) Stage III, 9 (23.1%) stage I and only a single TNM classification and staging e)
Age (years) Frequency Percent
? 40yrs 08 20.5
41-50yrs 12 30.8
51-60yrs 11 28.2
>61+ yrs 08 20.5
Total 39 100.0
Figure 3. Table 3 :
3
013
2
Year
39
Stage Stage I Stage II A Stage II B Stage III A Stage III B Stage IV Total Table 4 : Relation of sentinel and non-sentinel lymph node TNM Frequency Percent T1.N0.M0 09 23.1 T2.N0.M0 12 30.8 T3.N0.M0 03 07.7 T2.N1.M0 04 10.3 T3.N1.M0 05 12.8 T3.N2.M0 03 07.7 T4.N2.M0 02 05.1 T2.N0.M1 01 02.6 39 100% Volume XIII Issue IV Version I
Sentinel LN NS LN NSLN NSLN NSLN not Total ( D D D D ) I
SLN contain malignancy SLN does not contain SLN not found or reactive Total malignancy Count % within Sentinel LN % within NSLN % within NSLN Count % within Sentinel LN % within NSLN Count % within Sentinel LN % within NSLN Count % within Sentinel LN positive for malignancy 11 50.0% 100.0% 0.0% 00 0.0% 0.0% 11 28.2% 100.0% 00 0.0% negative for malignancy 11 50.0% 47.8% 34.8% 04 44.4% 17.4% 23 59.0% 100.0% 08 100.0% found 00 0.0% 0.0% 0.0% 05 55.6% 100.0% 05 12.8% 100.0% 00 0.0% 22 100.0% 56.4% 20.5% 09 100.0% 23.1% 39 100.0% 100.0% 08 100.0% Global Journal of Medical Research
P value 0.000
Figure 4. Table 2 :
2
Figure 5. Table 5 :
5
Parameter SLN P value NSLN
Age group 0.423
Occupation 0.007 0.025
Marital status 0.443
clinical presentation NS
TNM state 0.324
NSLN 0.000 0.000
T 0.274
N 0.278
M 0.181 0.031
IV. Discussion
1
2

Appendix A

Appendix A.1

Appendix B

  1. Methylene blue dye a safe and effective alternative for sentinel lymph node localization. Philip Varghese , Alga Talaat , Samira Rahman , Azad Akberali , Jennifer Mustafa , May . The Breast Journal 2008. 14 (1) p. .
  2. Clinical aspects of sentinel node biopsy. S Hiram , Cody . Breast Cancer Research 2001. 3 p. .
  3. Prediction of additional axillaries metastasis of breast cancer following sentinel lymph node surgery. Sonam Channi Karn Changsri , Lynn Prakash , Shikha Sandweiss , Bose . The Breast Journal 2004. 10 (5) p. .
Notes
1
© 2013 Global Journals Inc. (US) Non-Sentinel Lymph Nodes Status in Patients With Breast Cancer Operated at Omdurman Teaching Hospital
2
© 2013 Global Journals Inc. (US)
Date: 2013-05-15